Abstract: The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug/cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 ?m.
Abstract: Provided herein are dendrimers comprising: a core unit, five generations of building units which are lysine residues or analogues thereof, first terminal groups comprising a cabazitazel residue covalently attached to a diglycolyl linker group, and second terminal groups comprising a PEG group. Also provided herein are pharmaceutical compositions comprising the dendrimers, and methods and uses of the dendrimers in therapy of disorders such as cancers. Processes for making the dendrimers and intermediates are also provided.
Abstract: A nicotine lozenge provided herein includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix and nicotine or a derivative thereof dispersed in the soluble-fiber matrix. In some cases, a nicotine lozenge provided herein includes at least 40 weight percent of soluble fiber. In some cases, soluble fiber in a nicotine lozenge provided herein can include maltodextrin. The nicotine lozenge is adapted to release the nicotine or a derivative thereof from the body when the body is received within the oral cavity of an adult consumer and exposed to saliva. A method of making nicotine lozenges provided herein includes forming a molten mixture of at least 40 weight percent soluble fiber, nicotine, and less than 15 weight percent water while maintaining a mixture temperature of less than 150° C. and portioning the molten mixture into a plurality of nicotine lozenges. In some cases, the ingredients can be mixed to form the molten mixture in an extruder.
Type:
Grant
Filed:
June 10, 2020
Date of Patent:
September 14, 2021
Assignee:
Altria Client Services LLC
Inventors:
Feng Gao, Diane L. Gee, Phillip M. Hulan, Shuzhong Zhuang, William J. Burke
Abstract: The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.
Type:
Grant
Filed:
July 27, 2020
Date of Patent:
September 7, 2021
Assignee:
Calm Water Therapeutics LLC
Inventors:
Eugene Rex Cooper, David Maxwell Kleinman, Andrew Loxley, Mark A. Mitchnick
Abstract: A pharmaceutical composition is described. The composition may include: (i) a drug component including at least one pharmaceutically acceptable salt of glycopyrrolate; and (ii) a propellant component including 1,1-difluoroethane (HFA-152a).
Abstract: This invention relates to cocrystals of naloxone and of naltrexone and their use as opioid antagonists. The cocrystals of the invention include naloxone isonicotinamide cocrystal, naloxone hydrochloride piperazine cocrystal, naltrexone menthol cocrystal, naltrexone thymine cocrystal, naltrexone 2,5-dihydroxybenzoic acid cocrystal, naltrexone salicylic acid cocrystal, naltrexone hydrochloride piperazine cocrystal and naltrexone hydrochloride sulfathiazole cocrystal. A drug-in¬ adhesive transdermal patch containing the opioid analgesic fentanyl or an analog thereof and a cocrystal of naloxone or naltrexone is disclosed. Also disclosed is a method of treating pain, such as acute, chronic or intermittent pain, by applying a drug-in-adhesive transdermal patch of the invention to the skin of a patient in need thereof.
Type:
Grant
Filed:
September 26, 2016
Date of Patent:
August 24, 2021
Assignee:
Cassava Sciences, Inc.
Inventors:
Remi Barbier, Nadav Friedmann, Vijay Srirambhatla, Stephen Watt, Michael Zamloot
Abstract: A self-tanning composition for application to wetted skin after showering, and the like, which provides moisturizing and skin coloration, all over body spreadability, and easy application. The self-tanning composition comprises: a quaternary ammonium salt; a reducing sugar; and at least one silicone.
Type:
Grant
Filed:
August 25, 2016
Date of Patent:
August 17, 2021
Assignee:
Kao USA Inc.
Inventors:
Susan Littell, Emily Meiser, Wael Boutros
Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one salmeterol compound selected from salmeterol and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).
Abstract: A non-synthetic, hydrophilic, biodegradable, biocompatible polysaccharide based non-toxic anti-adhesion hydrogel barrier is disclosed herein. The barrier of the present invention is formed by constructing a unique interpenetrating, crosslinked network with a unique porosity. Furthermore, the barrier of the present invention is comprised of tunable biopolymers for controllable mechanical robustness and degradation. The barrier of the present invention effectively reduces unwanted adhesions using non-synthetic components.
Type:
Grant
Filed:
May 1, 2019
Date of Patent:
July 13, 2021
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: Provided is a low-cost, easy-to-handle, effective therapeutic agent for wounds that is a therapeutic agent for skin wounds or rough skin that includes at least one selected from the group consisting of zinc chloride, zinc hydroxide, and zinc oxide and may include a pharmaceutically acceptable carrier.
Abstract: Personal care and household care compositions comprising a conditioner and rheology modifier based on a cationic galactomannan or cationic xyloglucan having cationic degree of substitution comprised between 0.01 and 3, free from (3-chloro-2-hydroxypropyl)trimethyl ammonium chloride and free from (2,3-epoxypropyl) trimethyl ammonium chloride.
Type:
Grant
Filed:
August 29, 2019
Date of Patent:
May 4, 2021
Assignee:
Lamberti SPA
Inventors:
Valentina Langella, Mauro Riccaboni, Barbara Biasotti, Chiara Fumagalli, Giovanni Floridi, Giuseppe Li Bassi
Abstract: Described are transdermal drug delivery systems for the transdermal administration of tertiary amine drugs, such as rivastigmine, fentanyl or rotigotine, comprising a polymer matrix comprising a free base form of the drug and at least one carboxyl group-containing compound. In some embodiments, the systems include a rate-controlling membrane and a skin-contacting face adhesive apart from the polymer matrix.
Type:
Grant
Filed:
March 13, 2014
Date of Patent:
April 27, 2021
Assignee:
NOVEN PHARMACEUTICALS, INC.
Inventors:
Jun Liao, Takito Shima, Puchun Liu, Steven Dinh
Abstract: The present disclosure relates to the use of alkali metal salts and preferably lithium chloride for treatment of Varroa destructor infestation of honey bees.
Type:
Grant
Filed:
June 25, 2019
Date of Patent:
April 20, 2021
Assignees:
Universität Hohenheim, siTools Biotech GmbH
Inventors:
Stefan Hannus, Peter Rosenkranz, Bettina Ziegelmann
Abstract: A method for delivering a benefit agent to the surface of the eye, the method comprising applying an ocular benefit composition to a lid margin of the eye wherein the ocular benefit composition comprises at least 5 wt % of one or more lipid and/or lipid derived compounds.
Type:
Grant
Filed:
December 14, 2016
Date of Patent:
March 30, 2021
Assignee:
The University of Manchester
Inventors:
Philip Morgan, Carole Maldonado-Codina, Michael Read, Curtis Dobson
Abstract: This invention relates to a method of controlling the spread of dirofilariosis, such as for example heartworm, by administering to at least one non-human animal infested with filarioid nematodes such as Dirofilaria spp or susceptible to have been infested with filarioid nematodes such as Dirofilaria spp, an effective dose of a combination of a neonicotinoid compound and a pyrethroid compound.
Abstract: An effective dried attractive toxic bait station that acts as a lure and kill device for Ae. aegypti and other mosquitoes. The bait station is a simulated refuge at least part of which is coated with a dried mixture of poison and sugar forming a dried toxic sugar-containing bait. The simulated refuge attracts Ae. aegypti and other mosquitoes to bait station and encourages them to land on the coated portion. Once a mosquito has landed, it detects the sugar in the dried mixture of sugar and poison and ingests some of it. Once ingested, the dried mixture of poison and sugar will eventually kill the mosquito.
Type:
Grant
Filed:
July 23, 2019
Date of Patent:
March 23, 2021
Assignee:
Syracuse University
Inventors:
David Larsen, Anna Stewart, Marco Neira
Abstract: The invention discloses a double-layer tablet, wherein one layer has hole in which the ingredients of the other layer are filled; the number of said hole is 1-3, the diameters of the holes are 1-10 mm. Each layer of the double-layer tablet includes the active ingredients and the adjuvant materials and can be the rapid-release layer or sustained-release layer respectively. The preparation method: Preparing respectively a component I and a component II, both of them containing the active ingredients and the pharmaceutical excipients, and preparing the tablet having holes from component I; Forming the double-layer tablet composed of the component I layer and the component II layer after pressing said tablet having holes with the component II together; and filling the component II into the holes during compressing.
Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
Abstract: The invention discloses a double-layer tablet, wherein one layer has hole in which the ingredients of the other layer are filled; the number of said hole is 1-3, the diameters of the holes are 1-10 mm. Each layer of the double-layer tablet includes the active ingredients and the adjuvant materials and can be the rapid-release layer or sustained-release layer respectively. The preparation method: Preparing respectively a component I and a component II, both of them containing the active ingredients and the pharmaceutical excipients, and preparing the tablet having holes from component I; Forming the double-layer tablet composed of the component I layer and the component II layer after pressing said tablet having holes with the component II together; and filling the component II into the holes during compressing.
Abstract: An antibacterial device is disclosed that includes a substrate and an antibacterial coating or antibacterial surface being provided on at least a part of the substrate's surface. The antibacterial coating or surface includes Angstrom scale flakes, where the Angstrom scale flakes are arranged in a standing position on the substrate surface and are attached to the substrate surface via edge sides thereof. The Angstrom scale flakes can, for example, be graphene flakes, or graphite flakes having a thickness of a few atom layers. It has been found that such standing flakes are efficient in killing prokaryotic cells but do not harm eukaryotic cells.
Type:
Grant
Filed:
May 4, 2018
Date of Patent:
February 16, 2021
Assignee:
DENTSPLY IH AB
Inventors:
Martin Lovmar, Santosh Pandit, Venkata R. S. S. Mokkapati, Jie Sun